Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
Achilles Therapeutics plc - American Depositary Shares (ACHL)
Company Research
Source: GlobeNewswire
LONDON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced that the Company will be presenting at the following conference: 10th Annual Immuno-Oncology 360 Conference (IO360)Speaker: Sergio Quezada, PhD, Chief Scientific OfficerPresentation: Targeting Clonal Neoantigens with Precision Cell TherapiesLocation: New York Marriott at The Brooklyn Bridge, Brooklyn NY Date: February 29, 2024Time: 10:30am ET For more information about IO360, please visit https://io360summit.com. About Achilles Therapeutics Achilles is a clinical-stage biopharmaceutical company developing AI-Powered precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial
Show less
Read more
Impact Snapshot
Event Time:
ACHL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACHL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACHL alerts
High impacting Achilles Therapeutics plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ACHL
News
- Achilles Therapeutics plc (NASDAQ: ACHL) had its price target lowered by analysts at Chardan Capital from $11.00 to $6.00. They now have a "buy" rating on the stock.MarketBeat
- Achilles Therapeutics plc (NASDAQ: ACHL) was downgraded by analysts at Piper Sandler from an "overweight" rating to a "neutral" rating. They now have a $2.00 price target on the stock, down previously from $8.00.MarketBeat
- Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights [Yahoo! Finance]Yahoo! Finance
- Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business HighlightsGlobeNewswire
- Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning [Yahoo! Finance]Yahoo! Finance
ACHL
Earnings
- 4/4/24 - Miss
ACHL
Analyst Actions
- 4/5/24 - Chardan Capital
ACHL
Sec Filings
- 4/4/24 - Form S-8
- 4/4/24 - Form 20-F
- 3/29/24 - Form SC
- ACHL's page on the SEC website